Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Targeted Drug EGFR RTK Inhibitors for NSCLC market report explains the definition, types, applications, major countries, and major players of the Targeted Drug EGFR RTK Inhibitors for NSCLC market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Intas Pharmaceuticals
Pfizer
RPG Life Sciences
Beta Pharma
Zydus Cadila
ARIAD Pharmaceuticals (Takeda)
Genentech (Roche Group)
Cipla Pharma
Qilu Pharmaceutical
Genvio Pharma Limited
Alkem Laboratories
Natco Pharma
Mylan
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
OSI Pharmaceuticals
Drug International Limted
AstraZeneca
Teva
Fresenius Kabi India
Beacon Pharmaceuticals
Dr Reddy's Laboratories
Boehringer Ingelheim
Hetero Drugs
Glenmark Pharmaceuticals
By Type:
Icotinib
Gefitinib
Erlotinib
Afatinib
Osimertinib
Brigatinib
Other
By End-User:
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Outlook to 2028- Original Forecasts
-
2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Targeted Drug EGFR RTK Inhibitors for NSCLC Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market- Recent Developments
-
6.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market News and Developments
-
6.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Deals Landscape
7 Targeted Drug EGFR RTK Inhibitors for NSCLC Raw Materials and Cost Structure Analysis
-
7.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Raw Materials
-
7.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Price Trend of Key Raw Materials
-
7.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Suppliers of Raw Materials
-
7.4 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Rate of Raw Materials
-
7.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Cost Structure Analysis
-
7.5.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Raw Materials Analysis
-
7.5.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Labor Cost Analysis
-
7.5.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Manufacturing Expenses Analysis
8 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Import and Export Analysis (Top 10 Countries)
-
8.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Export by Region (Top 10 Countries) (2017-2028)
9 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Outlook by Types and Applications to 2022
-
9.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Icotinib Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Gefitinib Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Erlotinib Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Afatinib Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Osimertinib Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Brigatinib Consumption and Growth Rate (2017-2022)
-
9.1.7 Global Other Consumption and Growth Rate (2017-2022)
-
9.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Targeted Drug EGFR RTK Inhibitors for NSCLC Market Analysis and Outlook till 2022
-
10.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.2.2 Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.2.3 Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.2 UK Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.3 Spain Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.4 Belgium Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.5 France Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.6 Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.7 Denmark Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.8 Finland Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.9 Norway Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.10 Sweden Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.11 Poland Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.12 Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.13 Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.2 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.3 India Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.4 South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.5 Pakistan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.6 Bangladesh Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.7 Indonesia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.8 Thailand Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.9 Singapore Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.10 Malaysia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.11 Philippines Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.12 Vietnam Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.2 Colombia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.3 Chile Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.4 Argentina Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.5 Venezuela Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.6 Peru Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.7 Puerto Rico Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.8 Ecuador Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6.2 Kuwait Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6.3 Oman Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6.4 Qatar Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6.5 Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6.6 United Arab Emirates Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.7.2 South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.7.3 Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.7.4 Algeria Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
-
10.8.2 New Zealand Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)
11 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Competitive Analysis
-
11.1 Intas Pharmaceuticals
-
11.1.1 Intas Pharmaceuticals Company Details
-
11.1.2 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.1.4 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Pfizer
-
11.2.1 Pfizer Company Details
-
11.2.2 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.2.4 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 RPG Life Sciences
-
11.3.1 RPG Life Sciences Company Details
-
11.3.2 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.3.4 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Beta Pharma
-
11.4.1 Beta Pharma Company Details
-
11.4.2 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.4.4 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Zydus Cadila
-
11.5.1 Zydus Cadila Company Details
-
11.5.2 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.5.4 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 ARIAD Pharmaceuticals (Takeda)
-
11.6.1 ARIAD Pharmaceuticals (Takeda) Company Details
-
11.6.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.6.4 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Genentech (Roche Group)
-
11.7.1 Genentech (Roche Group) Company Details
-
11.7.2 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.7.4 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Cipla Pharma
-
11.8.1 Cipla Pharma Company Details
-
11.8.2 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.8.4 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Qilu Pharmaceutical
-
11.9.1 Qilu Pharmaceutical Company Details
-
11.9.2 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.9.4 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Genvio Pharma Limited
-
11.10.1 Genvio Pharma Limited Company Details
-
11.10.2 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.10.4 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Alkem Laboratories
-
11.11.1 Alkem Laboratories Company Details
-
11.11.2 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.11.4 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Natco Pharma
-
11.12.1 Natco Pharma Company Details
-
11.12.2 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.12.4 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Mylan
-
11.13.1 Mylan Company Details
-
11.13.2 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.13.4 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Everest Pharmaceuticals
-
11.14.1 Everest Pharmaceuticals Company Details
-
11.14.2 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.14.4 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Incepta Pharmaceuticals Limited
-
11.15.1 Incepta Pharmaceuticals Limited Company Details
-
11.15.2 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.15.4 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 OSI Pharmaceuticals
-
11.16.1 OSI Pharmaceuticals Company Details
-
11.16.2 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.16.4 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.16.5 Recent Research and Development Strategies
-
11.17 Drug International Limted
-
11.17.1 Drug International Limted Company Details
-
11.17.2 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.17.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.17.4 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.17.5 Recent Research and Development Strategies
-
11.18 AstraZeneca
-
11.18.1 AstraZeneca Company Details
-
11.18.2 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.18.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.18.4 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.18.5 Recent Research and Development Strategies
-
11.19 Teva
-
11.19.1 Teva Company Details
-
11.19.2 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.19.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.19.4 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.19.5 Recent Research and Development Strategies
-
11.20 Fresenius Kabi India
-
11.20.1 Fresenius Kabi India Company Details
-
11.20.2 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.20.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.20.4 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.20.5 Recent Research and Development Strategies
-
11.21 Beacon Pharmaceuticals
-
11.21.1 Beacon Pharmaceuticals Company Details
-
11.21.2 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.21.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.21.4 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.21.5 Recent Research and Development Strategies
-
11.22 Dr Reddy's Laboratories
-
11.22.1 Dr Reddy's Laboratories Company Details
-
11.22.2 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.22.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.22.4 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.22.5 Recent Research and Development Strategies
-
11.23 Boehringer Ingelheim
-
11.23.1 Boehringer Ingelheim Company Details
-
11.23.2 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.23.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.23.4 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.23.5 Recent Research and Development Strategies
-
11.24 Hetero Drugs
-
11.24.1 Hetero Drugs Company Details
-
11.24.2 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.24.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.24.4 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.24.5 Recent Research and Development Strategies
-
11.25 Glenmark Pharmaceuticals
-
11.25.1 Glenmark Pharmaceuticals Company Details
-
11.25.2 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.25.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
11.25.4 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
11.25.5 Recent Research and Development Strategies
12 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Outlook by Types and Applications to 2028
-
12.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Icotinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Gefitinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Erlotinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Afatinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Osimertinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Brigatinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.7 Global Other Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Targeted Drug EGFR RTK Inhibitors for NSCLC Market Analysis and Outlook to 2028
-
13.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.2.2 Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.2.3 Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.2 UK Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.3 Spain Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.4 Belgium Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.5 France Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.6 Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.7 Denmark Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.8 Finland Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.9 Norway Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.10 Sweden Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.11 Poland Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.12 Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.13 Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.2 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.3 India Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.4 South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.8 Thailand Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.9 Singapore Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.11 Philippines Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.2 Colombia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.3 Chile Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.4 Argentina Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.6 Peru Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6.3 Oman Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6.4 Qatar Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.7.2 South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.7.3 Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.7.4 Algeria Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Targeted Drug EGFR RTK Inhibitors for NSCLC
-
Figure of Targeted Drug EGFR RTK Inhibitors for NSCLC Picture
-
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Icotinib Consumption and Growth Rate (2017-2022)
-
Figure Global Gefitinib Consumption and Growth Rate (2017-2022)
-
Figure Global Erlotinib Consumption and Growth Rate (2017-2022)
-
Figure Global Afatinib Consumption and Growth Rate (2017-2022)
-
Figure Global Osimertinib Consumption and Growth Rate (2017-2022)
-
Figure Global Brigatinib Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Table North America Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure United States Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure UK Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Spain Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Belgium Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure France Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Denmark Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Finland Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Norway Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Sweden Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Poland Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure India Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Thailand Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Singapore Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Philippines Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table South America Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Colombia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Chile Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Argentina Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Peru Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table GCC Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure Bahrain Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Oman Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Qatar Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure Nigeria Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Algeria Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Oceania Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Intas Pharmaceuticals Company Details
-
Table Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table RPG Life Sciences Company Details
-
Table RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Beta Pharma Company Details
-
Table Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Zydus Cadila Company Details
-
Table Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table ARIAD Pharmaceuticals (Takeda) Company Details
-
Table ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Genentech (Roche Group) Company Details
-
Table Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Cipla Pharma Company Details
-
Table Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Qilu Pharmaceutical Company Details
-
Table Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Genvio Pharma Limited Company Details
-
Table Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Alkem Laboratories Company Details
-
Table Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Natco Pharma Company Details
-
Table Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Mylan Company Details
-
Table Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Everest Pharmaceuticals Company Details
-
Table Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Incepta Pharmaceuticals Limited Company Details
-
Table Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table OSI Pharmaceuticals Company Details
-
Table OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Drug International Limted Company Details
-
Table Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table AstraZeneca Company Details
-
Table AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Teva Company Details
-
Table Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Fresenius Kabi India Company Details
-
Table Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Beacon Pharmaceuticals Company Details
-
Table Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Dr Reddy's Laboratories Company Details
-
Table Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Boehringer Ingelheim Company Details
-
Table Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Hetero Drugs Company Details
-
Table Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Table Glenmark Pharmaceuticals Company Details
-
Table Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Main Business and Markets Served
-
Table Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Portfolio
-
Figure Global Icotinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Gefitinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Erlotinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Afatinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Osimertinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Brigatinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Table North America Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure United States Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
